(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its ...

No more waiting: Humira’s judgment day has finally arrived. The first Humira biosimilar, Amgen’s Amjevita, is set to reach the market Tuesday and kick off a tsunami-sized wave of competition. With ...

FILE - Packaging for AbbVie's drug, Humira. Humira-referenced biosimilars have been launched this year, but have thus far gained very little traction. (AP Photo/David J. Phillip, File) The blockbuster ...

You might call it the Swiss army knife of pharmaceutical drugs. Since it hit the market in 2002 to treat rheumatoid arthritis, Humira has racked up one governmental approval after another to treat ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Humira (adalimumab) has potential interactions with several other drugs. For example, taking prednisone with Humira can increase the risk of side effects from both drugs. Humira may also interact with ...

This week CVS Health launched Cordavis, a wholly owned subsidiary that will work with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market. The ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

While flashy growth stocks often steal the spotlight, some of the market’s most consistent winners are hiding in plain sight. This year, two Dividend Kings, companies with decades-long track records ...